Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Shionogi Pharma will pay $25 million upfront and up to $100 million in milestone payments for selective estrogen receptor modulator ospemifene, which it expects to file in the second half for the treatment of postmenopausal vulvovaginal atrophy.
You may also be interested in...
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Shionogi offers strong pipeline, Sciele brings 770-strong sales force to Japan-U.S. pairing.
QuatRx Anticipates NDA Filing For Vaginal Atrophy Therapy Ophena In 2009/2010
The non-estrogen treatment for postmenopausal women is a potential blockbuster, CEO Zerbe tells “The Pink Sheet” DAILY.